ADCY9 encodes adenylyl cyclase 9, a membrane-bound enzyme that catalyzes cAMP formation in response to G protein-coupled receptor activation 12. The protein participates in signaling cascades triggered by corticotropin-releasing factor, corticosteroids, and beta-adrenergic receptors 3. ADCY9 shows differential subcellular localization, with endosomal concentration in striatal neurons enabling selective nuclear PKA signaling 4. In disease contexts, ADCY9 polymorphisms significantly influence asthma susceptibility and severity. The rs1967309 locus associates with childhood asthma risk, particularly when combined with allergen exposure 5. The rs2601796 variant correlates with severe asthma and reduced bronchodilator responsiveness, likely through decreased ADCY9 expression in lung tissue 6. ADCY9 polymorphisms also modulate response to inhaled corticosteroid-long-acting beta-agonist combination therapy, with additive effects observed alongside ADRB2 variants 7. Cardiovascular studies demonstrate that ADCY9 inactivation reduces myocardial infarction-induced remodeling and dysfunction in mice 8. ADCY9 polymorphisms influence therapeutic responses to cholesterol ester transfer protein inhibitors in atherosclerosis management 9. Additionally, ADCY9 variants associate with metabolic phenotypes that uncouple obesity from cardiometabolic complications 10. Glucocorticoid-regulated ADCY9 expression supports stress response signaling in the brain 11.